The European healthcare technology and medical technology sectors have entered a period of definitive industrial maturity as of early 2026. This era is characterised by a fundamental shift away from the liquidity-fueled exuberance of the early 2020s toward a disciplined, metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility. Within this landscape, the role of financial advisory has undergone a r